메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
신호철 (중앙대학교) 박재홍 (중앙대학교 제약산업학과) 김지원 (중앙대학교 제약산업학과) 백다정 (중앙대학교 제약산업학과) 이윤지 (중앙대학교 약학대학) 정선영 (중앙대학교) 강원구 (중앙대학교 약학대학) 김하형 (중앙대학교 약학대학) 최영욱 (중앙대학교) 김은영 (중앙대학교)
저널정보
한국임상약학회 한국임상약학회지 한국임상약학회지 제31권 제3호
발행연도
2021.9
수록면
171 - 179 (9page)
DOI
https://doi.org/10.24304/kjcp.2021.31.3.171

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background: Need for regulatory science is emerging with the development of pharmaceutical industry. It is essential to trainregulatory science experts to meet the needs of technology and regulations to evaluate advanced products. Major regulatory sciencecountries are conducting the regulatory science activities and fostering the experts. Methods: Published literature and the relevantwebsite of European Union (EU) were reviewed and criteria were developed. In particular, we focused on in depth descriptions of theInnovative Medicines Initiative program, which was conducted twice. Results: EU is striving to provide funding and training expertsfor the development of the regulatory science by horizon 2020 and regulatory science to 2025. Innovative medicines initiative (IMI)is a public-private partnership aimed at the development of the pharmaceutical industry, including the regulatory science. IMIeducation and training projects have provided various education and training course including short-term curriculum and master anddoctoral course. The difference between South Korea’s regulatory science expert training project in 2021 and the EU’s IMI educationand training projects is participation of pharmaceutical companies. While the pharmaceutical companies participate in the IMIproject to select project topics and form a community, South Korea’s project is focused on the Ministry of Food and Drug Safety anduniversities. Conclusion: Through successful active networks with regulatory party, pharmaceutical companies, and universities, agreat innovative advance of regulatory science in South Korea is expected.

목차

등록된 정보가 없습니다.

참고문헌 (37)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0